These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 1710486)

  • 21. [Treatment effect of DICE regimen on patients with relapsed or refractory intermediate and high grade non-Hodgkin's lymphoma].
    Zhou SY; Shi YK; He XH; Zhang P; Dong M; Huang DZ; Yang JL; Zhang CG; Liu P; Yang S; Feng FY
    Ai Zheng; 2005 Apr; 24(4):465-9. PubMed ID: 15820071
    [TBL] [Abstract][Full Text] [Related]  

  • 22. DICE (dexamethasone, ifosfamide, cisplatin, etoposide) infusional chemotherapy for refractory or relapsed non-Hodgkin's lymphoma (NHL).
    Coleman M; Leonard J; Shuster MW; Kaufman TP
    Eur J Haematol Suppl; 2001 Jul; 64():41-5. PubMed ID: 11486401
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Failure of IMVP-16 as second-line treatment for relapsed or refractory high grade non-Hodgkin's lymphoma.
    De Lord C; Newland AC; Linch DC; Vaughan Hudson B; Vaughan Hudson G
    Hematol Oncol; 1992; 10(2):81-6. PubMed ID: 1592365
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
    Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
    Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma.
    Sandlund JT; Pui CH; Mahmoud H; Zhou Y; Lowe E; Kaste S; Kun LE; Krasin MJ; Onciu M; Behm FG; Ribeiro RC; Razzouk BI; Howard SC; Metzger ML; Hale GA; Rencher R; Graham K; Hudson MM
    Ann Oncol; 2011 Feb; 22(2):468-71. PubMed ID: 20624787
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etoposide, ifosfamide and methotrexate combination chemotherapy in patients with aggressive non-Hodgkin's lymphoma after failure of the LNH 84 regimen.
    Herbrecht R; Ortiz S; Damonte JC; Liu KL; Maloisel F; Dufour P; Bergerat JP; Oberling F
    Hematol Oncol; 1991; 9(4-5):253-7. PubMed ID: 1720760
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mesna/ifosfamide, mitoxantrone, etoposide, bleomycin, vincristine, prednisone (MINE-BOP) combination chemotherapy in the treatment of refractory and relapsed non-Hodgkin's lymphoma.
    Dinçol D; Içli F; Karaoğuz H; Cay F; Arican A; Demirkazik A; Akbulut H
    Acta Oncol; 1995; 34(7):937-40. PubMed ID: 7492384
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Experience with salvage regimens at M.D. Anderson Hospital.
    Cabanillas F
    Ann Oncol; 1991 Jan; 2 Suppl 1():31-2. PubMed ID: 1904269
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
    Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
    Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Multicentre combined chemotherapy protocol for large cell advanced non Hodgkin's lymphoma.
    Dumont J; Charpy-Validire P; Mosseri V; Gabarre J; Belanger C; Turpin F; Binet JL; Dreyfus F; Fourquet A; Janvier M
    Hematol Oncol; 1991; 9(4-5):197-207. PubMed ID: 1720759
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A brief-duration combination chemotherapy for elderly patients with poor-prognosis non-Hodgkin's lymphoma.
    McMaster ML; Johnson DH; Greer JP; Wolff SN; Hildreth CR; Greco FA; Hainsworth JD
    Cancer; 1991 Mar; 67(6):1487-92. PubMed ID: 1705861
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Toxicity and efficacy of ifosfamide, carboplatin and etoposide (modified ICE) as a salvage chemotherapy in Japanese patients with relapsed or refractory aggressive non-Hodgkin's lymphoma.
    Itoh K; Igarashi T; Ohtsu T; Wakita H; Watanabe Y; Fujii H; Minami H; Sasaki Y
    Int J Hematol; 1998 Dec; 68(4):431-7. PubMed ID: 9885442
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Combination salvage chemotherapy with MIZE (ifosfamide-mesna, idarubicin and etoposide) for relapsing or refractory lymphoma.
    Garay G; Dupont J; Dragosky M; Nucifora E; Cacchione R; Schnidrig P; Fernández J; Abel-Alzueta ; Riveros D; Noviello V; Bèguelin R; Campestri R; Albera C; Nicastro M; Triguboff E
    Leuk Lymphoma; 1997 Aug; 26(5-6):595-602. PubMed ID: 9389366
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of refractory and relapsed non-Hodgkin's lymphoma with ifosfamide, methotrexate and etoposide.
    Sangster G; Patton WN; Harris RI; Grieve RJ; Leyland MJ
    Cancer Chemother Pharmacol; 1989; 23(4):263-5. PubMed ID: 2924382
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ifosfamide and etoposide as salvage therapy for non-Hodgkin's lymphoma.
    Hagberg H; Cavallin-Ståhl E; Lind J
    Scand J Haematol; 1986 Jan; 36(1):61-4. PubMed ID: 3952466
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Chemotherapy of resistant and recurrent lymphoma based on a combination of ifosfamide and etoposide. Antitumor effects, toxicity and stimulation of peripheral stem cells].
    Mayer J; Korístek Z; Vásová I; Müllerová I; Král Z; Navrátil M; Klabusay M; Vorlícek J; Vodvárka P; Hejlová N; Penka M; Krahulcová E; Tomíska M; Adam Z; Hájek R
    Cas Lek Cesk; 1998 Oct; 137(19):590-7. PubMed ID: 9818471
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A prospective study of P-IMVP-16/CBDCA: a novel salvage chemotherapy for patients with aggressive non-Hodgkin's lymphoma who had previously received CHOP therapy as first-line chemotherapy.
    Sawada M; Tsurumi H; Yamada T; Hara T; Fukuno K; Goto H; Shimizu M; Kasahara S; Yoshikawa T; Kanemura N; Oyama M; Takami T; Moriwaki H
    Eur J Haematol; 2002 Jun; 68(6):354-61. PubMed ID: 12225393
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Salvage chemoimmunotherapy with rituximab, ifosfamide and etoposide (R-IE regimen) in patients with primary CNS lymphoma relapsed or refractory to high-dose methotrexate-based chemotherapy.
    Mappa S; Marturano E; Licata G; Frezzato M; Frungillo N; Ilariucci F; Stelitano C; Ferrari A; Sorarù M; Vianello F; Baldini L; Proserpio I; Foppoli M; Assanelli A; Reni M; Caligaris-Cappio F; Ferreri AJ
    Hematol Oncol; 2013 Sep; 31(3):143-50. PubMed ID: 23161567
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intensive weekly combination chemotherapy for patients with intermediate-grade and high-grade non-Hodgkin's lymphoma.
    Sweetenham JW; Mead GM; Whitehouse JM
    J Clin Oncol; 1991 Dec; 9(12):2202-9. PubMed ID: 1720454
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Ifosfamide, epirubicin, etoposide (IEV) and autologous peripheral blood progenitor cell transplant: a feasible and effective salvage treatment for lymphoid malignancies.
    Clavio M; Garrone A; Pierri I; Michelis GL; Balocco M; Albarello A; Varaldo R; Canepa P; Miglino M; Ballerini F; Canepa L; Gobbi M
    Oncol Rep; 2005 Oct; 14(4):933-40. PubMed ID: 16142354
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.